Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Jazz Pharmaceuticals plc’s stock clocked out at $107.82, down -0.42% from its previous closing price of $108.27. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 0.86 million shares were traded.
Ratios:
To gain a deeper understanding of JAZZ’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.39. For the most recent quarter (mrq), Quick Ratio is recorded 2.97 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 1.30 whereas as Long-Term Debt/Eq ratio is at 1.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on March 07, 2025, Upgraded its rating to Buy and sets its target price to $179 from $145 previously.
Wells Fargo Upgraded its Equal Weight to Overweight on February 13, 2025, whereas the target price for the stock was revised from $130 to $170.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 09 ’25 when Mulligan Seamus bought 100,000 shares for $98.26 per share. The transaction valued at 9,826,120 led to the insider holds 100,000 shares of the business.
Mulligan Seamus bought 1,621 shares of JAZZ for $166,962 on May 12 ’25. The Director now owns 101,621 shares after completing the transaction at $103.00 per share. On May 01 ’25, another insider, COZADD BRUCE C, who serves as the Chairman & CEO of the company, sold 1,000 shares for $116.35 each. As a result, the insider received 116,350 and left with 439,307 shares of the company.
Valuation Measures:
As of this moment, Jazz’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.54, and their Forward P/E ratio for the next fiscal year is 5.00. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.39. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.63 while its Price-to-Book (P/B) ratio in mrq is 1.59.
Stock Price History:
Over the past 52 weeks, JAZZ has reached a high of $148.06, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is -6.63%, while the 200-Day Moving Average is calculated to be -9.07%.
Shares Statistics:
A total of 61.62M shares are outstanding, with a floating share count of 58.73M. Insiders hold about 4.71% of the company’s shares, while institutions hold 97.50% stake in the company.
Earnings Estimates
At present, 15.0 analysts are actively evaluating the performance of Jazz Pharmaceuticals plc (JAZZ) in the stock market.The consensus estimate for the next quarter is $5.05, with high estimates of $6.08 and low estimates of $1.51.
Analysts are recommending an EPS of between $5.8 and $4.18 for the fiscal current year, implying an average EPS of $5.01. EPS for the following year is $21.46, with 15.0 analysts recommending between $25.09 and $15.78.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $1.05B. It ranges from a high estimate of $1.14B to a low estimate of $988.65M. As of the current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.02BFor the next quarter, 16 analysts are estimating revenue of $1.1B. There is a high estimate of $1.16B for the next quarter, whereas the lowest estimate is $1.05B.
A total of 18 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.4B, while the lowest revenue estimate was $4.03B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 18 analysts’ estimates, the company’s revenue will be $4.4B in the next fiscal year. The high estimate is $4.74B and the low estimate is $3.87B.
